# ZORYVE (roflumilast) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/roflumilast

> The PDUFA target action date for ZORYVE (roflumilast), sponsored by Arcutis Biotherapeutics, Inc. (ARQT), is February 23, 2027, for infants with atopic dermatitis down. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the ZORYVE (roflumilast) PDUFA date?

The PDUFA target action date for ZORYVE (roflumilast), sponsored by Arcutis Biotherapeutics, Inc. (ARQT), is February 23, 2027, for infants with atopic dermatitis down. Status: scheduled. Press release filed with the SEC (EX-99): "•The FDA has set a target action date of February 23, 2027, for the supplemental New Drug Application to expand the indication for ZORYVE cream 0.05% for mild to moderate atopic dermatitis to infants aged 3 to 24 months." Last confirmed November 4, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/roflumilast)

Source: Press release filed with the SEC (EX-99), accession 0001787306-26-000056, https://www.sec.gov/Archives/edgar/data/1787306/000178730626000056/pressreleaseex991q32026.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/pdufa/roflumilast#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | ZORYVE (roflumilast) |
| Codes |  |
| Sponsor | Arcutis Biotherapeutics, Inc. (ARQT) https://sec-api.dev/companies/arqt/catalysts |
| Indications | seborrheic dermatitis in individuals aged 9 years and older, with no limitation, [plaque psoriasis in children down](https://sec-api.dev/indications/plaque-psoriasis-in-children-down), infants with atopic dermatitis down, [plaque psoriasis](https://sec-api.dev/indications/plaque-psoriasis), vitiligo and decision, vitiligo and share its decision |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### July 29, 2022: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215985 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20220729, review_priority STANDARD; sponsor_name ARCUTIS; product ZORYVE (ROFLUMILAST)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215985%22

### Sep 2022: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2025-02-25, last confirmed 2025-05-06.
- SEC Form 10-Q (accession 0001787306-25-000092): "We announced positive Phase 3 topline data in September 2022, with ZORYVE foam showing rapid disease clearance and significant reduction in itch." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000092/arqt-20250331.htm
- SEC Form 10-K (accession 0001787306-25-000029): "We announced positive topline data in September 2022, with ZORYVE foam showing rapid disease clearance and significant reduction in itch." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000029/arqt-20241231.htm

### October 5, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact. Indication: plaque psoriasis.
- First seen 2025-02-25, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215985 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20231005, review_priority STANDARD; sponsor_name ARCUTIS; product ZORYVE (ROFLUMILAST)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215985%22
- SEC Form 10-K (accession 0001787306-25-000029): "On October 6, 2023, we announced FDA approval of our sNDA to expand the indication of ZORYVE cream for the treatment of plaque psoriasis, including psoriasis in intertriginous areas, to children ages 6 to 11 years of age." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000029/arqt-20241231.htm
- SEC Form 10-K (accession 0001787306-25-000029): "In October 2023, we announced FDA approval of our sNDA to expand the indication of ZORYVE cream for the treatment of plaque psoriasis, including psoriasis in intertriginous areas (e.g., groin or axillae), to children ages 6 to 11 years of age." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000029/arqt-20241231.htm
- SEC Form 10-Q (accession 0001787306-26-000040): "In October 2023, we received FDA approval for an expanded indication in plaque psoriasis down to 6 years of age." https://www.sec.gov/Archives/edgar/data/1787306/000178730626000040/arqt-20260331.htm
- SEC Form 10-K (accession 0001787306-26-000018): "In October 2023, we received FDA approval for an expanded indication in plaque psoriasis down to 6 years of age." https://www.sec.gov/Archives/edgar/data/1787306/000178730626000018/arqt-20251231.htm
- SEC Form 10-Q (accession 0001787306-25-000144): "In October 2023, we received FDA approval for an expanded indication in plaque psoriasis down to 6 years of age." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000144/arqt-20250930.htm
- SEC Form 10-Q (accession 0001787306-25-000124): "In October 2023, we received FDA approval for an expanded indication in plaque psoriasis down to 6 years of age." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000124/arqt-20250630.htm
- SEC Form 10-Q (accession 0001787306-25-000092): "In October 2023, we received FDA approval for an expanded indication in plaque psoriasis down to 6 years of age." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000092/arqt-20250331.htm
- SEC Form 10-K (accession 0001787306-25-000029): "In October 2023, we received FDA approval for an expanded indication in plaque psoriasis down to 6 years of age." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000029/arqt-20241231.htm

### December 15, 2023: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: seborrheic dermatitis in individuals aged 9 years and older, with no limitation.
- First seen 2025-02-25, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA217242 ORIG-1 (Type 3 - New Dosage Form and Type 4 - New Combination): submission_status AP, submission_status_date 20231215, review_priority STANDARD; sponsor_name ARCUTIS; product ZORYVE (ROFLUMILAST)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217242%22
- SEC Form 10-Q (accession 0001787306-26-000051): "In December 2023, we received FDA approval for ZORYVE foam 0.3% (ZORYVE foam) for the treatment of seborrheic dermatitis in individuals aged 9 years and older, with no limitation on severity, location, or duration of use." https://www.sec.gov/Archives/edgar/data/1787306/000178730626000051/arqt-20260630.htm
- SEC Form 10-Q (accession 0001787306-26-000040): "In December 2023, we received FDA approval for ZORYVE foam 0.3% (ZORYVE foam) for the treatment of seborrheic dermatitis in individuals aged 9 years and older, with no limitation on severity, location, or duration of use." https://www.sec.gov/Archives/edgar/data/1787306/000178730626000040/arqt-20260331.htm
- SEC Form 10-K (accession 0001787306-26-000018): "In December 2023, we received FDA approval for ZORYVE foam 0.3% for the treatment of seborrheic dermatitis in individuals aged 9 years and older, with no limitation on severity, location, or duration of use." https://www.sec.gov/Archives/edgar/data/1787306/000178730626000018/arqt-20251231.htm
- SEC Form 10-Q (accession 0001787306-25-000144): "In December 2023, we received FDA approval for ZORYVE® (roflumilast) topical foam 0.3% (ZORYVE foam) for the treatment of seborrheic dermatitis in individuals aged 9 years and older, with no limitation on severity, location, or duration of use." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000144/arqt-20250930.htm
- SEC Form 10-Q (accession 0001787306-25-000124): "In December 2023, we received FDA approval for ZORYVE® (roflumilast) topical foam 0.3% (ZORYVE foam) for the treatment of seborrheic dermatitis in individuals aged 9 years and older, with no limitation on severity, location, or duration of use." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000124/arqt-20250630.htm
- SEC Form 10-Q (accession 0001787306-25-000092): "In December 2023, we received FDA approval for ZORYVE® (roflumilast) topical foam 0.3% (ZORYVE foam) for the treatment of seborrheic dermatitis in individuals aged 9 years and older, with no limitation on severity, location, or duration of use." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000092/arqt-20250331.htm
- SEC Form 10-K (accession 0001787306-25-000029): "In December 2023, we received FDA approval for ZORYVE® (roflumilast) topical foam 0.3% (ZORYVE foam) for the treatment of seborrheic dermatitis in individuals aged 9 years and older, with no limitation on severity, location, or duration of use." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000029/arqt-20241231.htm
- SEC Form 10-K (accession 0001787306-25-000029): "In December 2023, we received FDA approval for ZORYVE foam for the treatment of seborrheic dermatitis in individuals aged 9 years and older." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000029/arqt-20241231.htm
- SEC Form 10-K (accession 0001787306-25-000029): "In December 2023, we received FDA approval for ZORYVE foam for the treatment of seborrheic dermatitis in individuals aged 9 years and older, with no limitation on severity, location, or duration of use." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000029/arqt-20241231.htm

### Jul 2024: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-02-25, last confirmed 2025-10-28.
- SEC Form 10-Q (accession 0001787306-25-000144): "In addition to the approval of ZORYVE cream 0.3% for plaque psoriasis and ZORYVE foam for seborrheic dermatitis and plaque psoriasis of the scalp and body, we also received FDA approval for and commercially launched ZORYVE (roflumilast) cream 0.15% (ZORYVE cream 0.15%) in July 2024 for the treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older, with no limitation on location, body surface area treated, concomitant use, or duration of use specified in the approved labelling." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000144/arqt-20250930.htm
- SEC Form 10-Q (accession 0001787306-25-000124): "In addition to the approval of ZORYVE cream 0.3% for plaque psoriasis and ZORYVE foam for seborrheic dermatitis and plaque psoriasis of the scalp and body, we also received FDA approval for and commercially launched ZORYVE (roflumilast) cream 0.15% (ZORYVE cream 0.15%) in July 2024 for the treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older, with no limitation on location, body surface area treated, concomitant use, or duration of use specified in the approved labelling." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000124/arqt-20250630.htm
- SEC Form 10-Q (accession 0001787306-25-000092): "In addition to the approval of ZORYVE cream 0.3% for plaque psoriasis and ZORYVE foam for seborrheic dermatitis, we also received FDA approval for and commercially launched ZORYVE (roflumilast) cream 0.15% (ZORYVE cream 0.15%), (collectively, ZORYVE), in July 2024 for the treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older, with no limitation on location, body surface area treated, concomitant use, or duration of use specified in the approved labelling." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000092/arqt-20250331.htm
- SEC Form 10-K (accession 0001787306-25-000029): "In addition to the approval of ZORYVE cream 0.3% for plaque psoriasis and ZORYVE foam for seborrheic dermatitis, we also received FDA approval for and commercially launched ZORYVE (roflumilast) cream 0.15% (ZORYVE cream 0.15%), (collectively, ZORYVE), in July 2024 for the treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older, with no limitation on location, body surface area treated, concomitant use, or duration of use specified in the approved labelling." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000029/arqt-20241231.htm

### July 9, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215985 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20240709, review_priority STANDARD; sponsor_name ARCUTIS; product ZORYVE (ROFLUMILAST)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215985%22

### Dec 2024: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-02-25, last confirmed 2025-08-06.
- SEC Form 10-Q (accession 0001787306-25-000124): "Based on the positive results from the INTEGUMENT-PED study, and given our recent approval of ZORYVE cream 0.15% for the treatment of mild to moderate atopic dermatitis in individuals 6 years of age or older, we submitted a supplemental new drug application (sNDA) for topical ZORYVE cream 0.05% for children 2 to 5 years of age in December 2024, which was accepted by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date in October 2025." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000124/arqt-20250630.htm
- SEC Form 10-Q (accession 0001787306-25-000092): "Table of Contents age or older, we submitted a supplemental new drug application (sNDA) for topical ZORYVE cream 0.05% for children 2 to 5 years of age in December 2024, which was accepted by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date in October 2025." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000092/arqt-20250331.htm
- SEC Form 10-K (accession 0001787306-25-000029): "Based on the positive results from the INTEGUMENT-PED study, and given our recent approval of ZORYVE cream 0.15% for the treatment of mild to moderate atopic dermatitis in individuals 6 years of age or older, we submitted a supplemental new drug application (sNDA) for topical ZORYVE cream 0.05% for children 2 to 5 years of age in December 2024." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000029/arqt-20241231.htm

### May 22, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact. Stage: 2.
- First seen 2025-02-25, last confirmed 2025-05-06.
- Press release filed with the SEC (EX-99) (accession 0001787306-25-000091): "•The Company submitted an sNDA for ZORYVE foam for scalp and body psoriasis to the FDA based on the positive results from the pivotal ARRECTOR Phase 3 trial and a Phase 2b trial, and has been assigned a PDUFA action date of May 22, 2025." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000091/pressreleaseex991q12025.htm
- Press release filed with the SEC (EX-99) (accession 0001787306-25-000028): "•The Company submitted an sNDA for ZORYVE foam for scalp and body psoriasis to the FDA based on the positive results from the pivotal ARRECTOR Phase 3 trial and a Phase 2b trial, which was accepted by the FDA in September with a PDUFA action date set for May 22, 2025." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000028/pressreleaseex991q42024.htm
- Press release filed with the SEC (EX-99) (accession 0001787306-25-000091): "•May 22, 2025 Prescription Drug User Fee Act (PDUFA) action date for ZORYVE foam 0.3% for treatment of individuals with plaque psoriasis of the scalp and body, 12 years and older" https://www.sec.gov/Archives/edgar/data/1787306/000178730625000091/pressreleaseex991q12025.htm
- SEC Form 10-Q (accession 0001787306-25-000092): "Based on the ARRECTOR results and a Phase 2b study, we submitted an sNDA to the FDA for a label expansion to include scalp and body psoriasis in adults and adolescents ages 12 and over, which was accepted by the FDA with a PDUFA target action date of May 22, 2025." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000092/arqt-20250331.htm
- SEC Form 10-K (accession 0001787306-25-000029): "Based on the ARRECTOR results and a Phase 2b study, we submitted an sNDA to the FDA for a label expansion to include scalp and body psoriasis in adults and adolescents ages 12 and over, which was recently accepted by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date in May 2025." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000029/arqt-20241231.htm
- SEC Form 10-K (accession 0001787306-25-000029): "We announced positive topline data from our Phase 3 scalp and body psoriasis trial in September 2022, and we submitted an sNDA to the FDA for a label expansion to include scalp and body psoriasis in adults and adolescents ages 12 and over, which was accepted by the FDA with a PDUFA target action date in May 2025." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000029/arqt-20241231.htm
- openFDA Drugs@FDA: "NDA217242 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20250522, review_priority STANDARD; sponsor_name ARCUTIS; product ZORYVE (ROFLUMILAST)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217242%22

### May 22, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2025-08-06, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA217242 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20250522, review_priority STANDARD; sponsor_name ARCUTIS; product ZORYVE (ROFLUMILAST)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217242%22
- Press release filed with the SEC (EX-99) (accession 0001787306-25-000122): "•The Company received FDA approval for its sNDA for ZORYVE foam for scalp and body psoriasis in adult and adolescents 12 years of age and older in May 2025 and commenced sales in June 2025." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000122/pressreleaseex991q22025.htm

### Jun 2025: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-08-06, last confirmed 2025-10-28.
- SEC Form 10-Q (accession 0001787306-25-000144): "In June 2025, we initiated INTEGUMENT-INFANT, a Phase 2 study to evaluate the safety and efficacy of investigational ZORYVE cream 0.05% in infants as young as 3 months to less than 2 years with atopic dermatitis, which potentially could serve as the basis for a further expansion of the indication for ZORYVE cream 0.05% to this group of patients." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000144/arqt-20250930.htm
- SEC Form 10-Q (accession 0001787306-25-000124): "In June 2025, we initiated INTEGUMENT-INFANT, a Phase 2 study to evaluate the safety and efficacy of investigational ZORYVE cream 0.05% in infants as young as 3 months to less than 2 years with atopic dermatitis, which potentially could serve as the basis for a further expansion of the indication for ZORYVE cream 0.05% to this group of patients." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000124/arqt-20250630.htm

### Sep 2025: NDA/BLA submission

- Status: completed. Date confidence: month. Indication: plaque psoriasis in children down.
- First seen 2025-10-28, last confirmed 2025-10-28.
- SEC Form 10-Q (accession 0001787306-25-000144): "In September 2025, we submitted a supplemental New Drug Application (sNDA) to FDA to expand the indication of ZORYVE cream 0.3% for the treatment of plaque psoriasis in children down to the age of 2." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000144/arqt-20250930.htm

### October 4, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215985 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20251004, review_priority STANDARD; sponsor_name ARCUTIS; product ZORYVE (ROFLUMILAST)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215985%22

### October 13, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact. Indication: atopic dermatitis in children ages 2 to 5 with an.
- First seen 2025-02-25, last confirmed 2025-08-06.
- Press release filed with the SEC (EX-99) (accession 0001787306-25-000122): "•The Company has been assigned a Prescription Drug User Fee Act (PDUFA) action date of October 13, 2025 for the supplemental New Drug Application (sNDA) for ZORYVE cream 0.05% for the treatment of atopic dermatitis in children ages 2 to 5 years old." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000122/pressreleaseex991q22025.htm
- Press release filed with the SEC (EX-99) (accession 0001787306-25-000091): "•The Company submitted an supplemental New Drug Application (sNDA) for ZORYVE cream 0.05% to the FDA for the treatment of atopic dermatitis in children ages 2 to 5, and has been assigned a PDUFA action date of October 13, 2025." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000091/pressreleaseex991q12025.htm
- Press release filed with the SEC (EX-99) (accession 0001787306-25-000028): "•The Company submitted an sNDA for ZORYVE cream 0.05% to the FDA for the treatment of atopic dermatitis in children ages 2 to 5 with an anticipated target action date in Q4 of 2025, if accepted as submitted." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000028/pressreleaseex991q42024.htm
- SEC Form 10-Q (accession 0001787306-25-000124): "Based on the positive results from the INTEGUMENT-PED study, and given our recent approval of ZORYVE cream 0.15% for the treatment of mild to moderate atopic dermatitis in individuals 6 years of age or older, we submitted a supplemental new drug application (sNDA) for topical ZORYVE cream 0.05% for children 2 to 5 years of age in December 2024, which was accepted by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date in October 2025." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000124/arqt-20250630.htm
- SEC Form 10-Q (accession 0001787306-25-000092): "Table of Contents age or older, we submitted a supplemental new drug application (sNDA) for topical ZORYVE cream 0.05% for children 2 to 5 years of age in December 2024, which was accepted by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date in October 2025." https://www.sec.gov/Archives/edgar/data/1787306/000178730625000092/arqt-20250331.htm
- openFDA Drugs@FDA: "NDA215985 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20251004, review_priority STANDARD; sponsor_name ARCUTIS; product ZORYVE (ROFLUMILAST)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215985%22

### Nov 2025: NDA/BLA acceptance

- Status: completed. Date confidence: month. Indication: plaque psoriasis in children down.
- First seen 2026-02-25, last confirmed 2026-05-06.
- SEC Form 10-Q (accession 0001787306-26-000040): "In November 2025, our supplemental New Drug Application (sNDA) was accepted for filing by the FDA to potentially expand the indication of ZORYVE cream 0.3% for the treatment of plaque psoriasis in children down to the age of 2, with a Prescription Drug User Fee Act (PDUFA) target action date assigned for June 29, 2026." https://www.sec.gov/Archives/edgar/data/1787306/000178730626000040/arqt-20260331.htm
- SEC Form 10-K (accession 0001787306-26-000018): "In November 2025, our supplemental New Drug Application (sNDA) was accepted for filing by the FDA to potentially expand the indication of ZORYVE cream 0.3% for the treatment of plaque psoriasis in children down to the age of 2, with a Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026." https://www.sec.gov/Archives/edgar/data/1787306/000178730626000018/arqt-20251231.htm

### Feb 2026: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2026-05-06, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0001787306-26-000057): "•In February 2026, we announced positive topline data for INTEGUMENT-INFANT, a Phase 2 study evaluating the safety and efficacy of investigational ZORYVE cream 0.05% in infants as young as 3 months to less than 2 years of age with atopic dermatitis." https://www.sec.gov/Archives/edgar/data/1787306/000178730626000057/arqt-20260930.htm
- SEC Form 10-Q (accession 0001787306-26-000051): "In February 2026, we announced positive top-line data for INTEGUMENT-INFANT, a Phase 2 study evaluating the safety and efficacy of investigational ZORYVE cream 0.05% in infants as young as 3 months to less than 2 years of age with atopic dermatitis." https://www.sec.gov/Archives/edgar/data/1787306/000178730626000051/arqt-20260630.htm
- SEC Form 10-Q (accession 0001787306-26-000040): "In February 2026, we announced positive topline data for INTEGUMENT-INFANT, a Phase 2 study evaluating the safety and efficacy of investigational ZORYVE cream 0.05% in infants as young as 3 months to less than 2 years of age with atopic dermatitis." https://www.sec.gov/Archives/edgar/data/1787306/000178730626000040/arqt-20260331.htm

### Q2 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2026-02-25, last confirmed 2026-02-25.
- Press release filed with the SEC (EX-99) (accession 0001787306-26-000017): "The Company plans to submit an sNDA for ZORYVE cream 0.05% for this age group in Q2 2026." https://www.sec.gov/Archives/edgar/data/1787306/000178730626000017/pressreleaseex991q42025.htm

### June 29, 2026: PDUFA date

- Status: completed, approved. Date confidence: exact. Indication: plaque psoriasis in children down.
- First seen 2026-02-25, last confirmed 2026-05-06.
- Press release filed with the SEC (EX-99) (accession 0001787306-26-000017): "•sNDA accepted for ZORYVE cream 0.3% for the treatment of plaque psoriasis down to 2 years of age with a Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026." https://www.sec.gov/Archives/edgar/data/1787306/000178730626000017/pressreleaseex991q42025.htm
- SEC Form 10-Q (accession 0001787306-26-000040): "In November 2025, our supplemental New Drug Application (sNDA) was accepted for filing by the FDA to potentially expand the indication of ZORYVE cream 0.3% for the treatment of plaque psoriasis in children down to the age of 2, with a Prescription Drug User Fee Act (PDUFA) target action date assigned for June 29, 2026." https://www.sec.gov/Archives/edgar/data/1787306/000178730626000040/arqt-20260331.htm
- SEC Form 10-K (accession 0001787306-26-000018): "In November 2025, our supplemental New Drug Application (sNDA) was accepted for filing by the FDA to potentially expand the indication of ZORYVE cream 0.3% for the treatment of plaque psoriasis in children down to the age of 2, with a Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026." https://www.sec.gov/Archives/edgar/data/1787306/000178730626000018/arqt-20251231.htm
- SEC Form 10-K (accession 0001787306-26-000018): "Additionally, ZORYVE cream 0.3% for 2-5 year olds with plaque psoriasis has a PDUFA target action date of June 29, 2026." https://www.sec.gov/Archives/edgar/data/1787306/000178730626000018/arqt-20251231.htm
- openFDA Drugs@FDA: "NDA215985 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20260629, review_priority STANDARD; sponsor_name ARCUTIS; product ZORYVE (ROFLUMILAST)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215985%22

### June 29, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact. Indication: children with plaque psoriasis down.
- First seen 2026-08-05, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215985 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20260629, review_priority STANDARD; sponsor_name ARCUTIS; product ZORYVE (ROFLUMILAST)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215985%22
- Press release filed with the SEC (EX-99) (accession 0001787306-26-000049): "•The Company received U.S. Food and Drug Administration (FDA) approval of the Supplemental New Drug Application (sNDA) for ZORYVE cream 0.3% for the expanded indication to treat children with plaque psoriasis down to the age of 2 in June 2026, representing the seventh FDA approval for the Company since 2022." https://www.sec.gov/Archives/edgar/data/1787306/000178730626000049/pressreleaseex991q22026.htm

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: vitiligo with disclosure of topline results and decision.
- First seen 2026-08-05, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001787306-26-000056): "•Remains on track to disclose topline results from Phase 2 trial of ZORYVE foam 0.3% in individuals with vitiligo and decision on program advancement in Q4 of 2026" https://www.sec.gov/Archives/edgar/data/1787306/000178730626000056/pressreleaseex991q32026.htm
- Press release filed with the SEC (EX-99) (accession 0001787306-26-000049): "•Completed enrollment of the Phase 2 trial of ZORYVE foam 0.3% in individuals with vitiligo with disclosure of topline results and decision on program advancement anticipated in Q4 of 2026" https://www.sec.gov/Archives/edgar/data/1787306/000178730626000049/pressreleaseex991q22026.htm
- Press release filed with the SEC (EX-99) (accession 0001787306-26-000056): "•The Company remains on track to disclose topline results from the Phase 2 proof-of-concept study of ZORYVE foam 0.3% for the treatment of vitiligo and share its decision on program advancement by the end of 2026." https://www.sec.gov/Archives/edgar/data/1787306/000178730626000056/pressreleaseex991q32026.htm

### February 23, 2027: PDUFA date

- Status: scheduled. Date confidence: exact. Indication: infants with atopic dermatitis down.
- First seen 2026-08-05, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001787306-26-000056): "•The FDA has set a target action date of February 23, 2027, for the supplemental New Drug Application to expand the indication for ZORYVE cream 0.05% for mild to moderate atopic dermatitis to infants aged 3 to 24 months." https://www.sec.gov/Archives/edgar/data/1787306/000178730626000056/pressreleaseex991q32026.htm
- Press release filed with the SEC (EX-99) (accession 0001787306-26-000049): "•FDA accepted sNDA for ZORYVE cream 0.05% to expand indication to include infants with mild to moderate atopic dermatitis aged 3 to 24 months and set target action date of February 23, 2027" https://www.sec.gov/Archives/edgar/data/1787306/000178730626000049/pressreleaseex991q22026.htm
- Press release filed with the SEC (EX-99) (accession 0001787306-26-000049): "•The FDA accepted an sNDA for ZORYVE cream 0.05% to expand the indication for the treatment of mild to moderate atopic dermatitis in infants aged 3 to 24 months with a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027." https://www.sec.gov/Archives/edgar/data/1787306/000178730626000049/pressreleaseex991q22026.htm
- SEC Form 10-Q (accession 0001787306-26-000057): "We submitted a supplemental New Drug Application (sNDA) to the FDA based on the results of this trial to potentially expand the indication for ZORYVE cream 0.05% for the treatment of infants with atopic dermatitis down to the age of 3 months, which has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027." https://www.sec.gov/Archives/edgar/data/1787306/000178730626000057/arqt-20260930.htm
- SEC Form 10-Q (accession 0001787306-26-000051): "We submitted a Supplemental New Drug Application (sNDA) to the FDA based on the results of this trial to potentially expand the indication for ZORYVE cream 0.05% for the treatment of infants with atopic dermatitis down to the age of 3 months, which has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027." https://www.sec.gov/Archives/edgar/data/1787306/000178730626000051/arqt-20260630.htm

Calendar months: [February 2027](https://sec-api.dev/fda-calendar/2027-02)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/roflumilast.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ZORYVE (roflumilast) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/roflumilast

```bibtex
@misc{secapidev_pdufa_roflumilast_20261116,
  title        = {ZORYVE (roflumilast) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/roflumilast}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_roflumilast_20261116","title":"ZORYVE (roflumilast) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/roflumilast","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
